Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study
Journal of Stroke · 30.09.2023 · 25 (3) · 371-377
DOI: 10.5853/jos.2023.00668 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Stroke, erschienen am 30.09.2023. Verfasst von Lu Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Project Plan of Liao Ning Province.
Themen: Schlaganfall
Abstract (Originalsprache)
Background and Purpose Intravenous tenecteplase (TNK) efficacy has not been well demonstrated in acute ischemic stroke (AIS) beyond 4.5 hours after onset. This study aimed to determine the effect of intravenous TNK for AIS within 4.5 to 24 hours of onset.
Methods
In this pilot trial, eligible AIS patients with diffusion-weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch were randomly allocated to intravenous TNK (0.25 mg/kg) or standard care within 4.5–24 hours of onset. The primary endpoint was excellent functional outcome at 90 days (modified Rankin Scale [mRS] score of 0–1). The primary safety endpoint was symptomatic intracranial hemorrhage (sICH).
Results
Of the randomly assigned 80 patients, the primary endpoint occurred in 52.5% (21/40) of TNK group and 50.0% (20/40) of control group, with no significant difference (unadjusted odds ratio, 1.11; 95% confidence interval 0.46–2.66; P=0.82). More early neurological improvement occurred in TNK group than in control group (11 vs. 3, P=0.03), but no significant differences were found in other secondary endpoints, such as mRS 0–2 at 90 days, shift analysis of mRS at 90 days, and change in National Institutes of Health Stroke Scale score at 24 hours and 7 days. There were no cases of sICH in this trial; however, asymptomatic intracranial hemorrhage occurred in 3 of the 40 patients (7.5%) in the TNK group.
Conclusion
This phase 2, randomized, multicenter study suggests that intravenous TNK within 4.5–24 hours of onset may be safe and feasible in AIS patients with a DWI-FLAIR mismatch.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Neurology, Liaoning Health Industry Group Fukuang General Hospital, Fushun, China.
- Department of Neurology, Lvshunkou Traditional Chinese Medicine Hospital, Dalian, China.
- Department of Neurology, Liaoning Health Industry Group Fuxinkuang General Hospital, Fuxin, China.
- Department of Neurology, Haicheng Traditional Chinese Medicine Hospital, Haicheng, China.
- Department of Neurology, Huludao Second People's Hospital, Huludao, China.
Förderung
- Science and Technology Project Plan of Liao Ning Province
Zitieren
APA
Wang, L., Dai, Y. J., Cui, Y., Zhang, H., Jiang, C. H., Duan, Y. J., Zhao, Y., Feng, Y. F., Geng, S. M., Zhang, Z. H., Lu, J., Zhang, P., Zhao, L. W., Zhao, H., Ma, Y. T., Song, C. G., Zhang, Y., & Chen, H. S. (2023). Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study. Journal of Stroke, 25(3), 371-377. https://doi.org/10.5853/jos.2023.00668
Vancouver
Wang L, Dai YJ, Cui Y, Zhang H, Jiang CH, Duan YJ, et al. Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study. Journal of Stroke. 2023;25(3):371-377. doi:10.5853/jos.2023.00668
BibTeX
@article{Wang2023,
author = {Wang, Lu and Dai, Ying-Jie and Cui, Yu and Zhang, Hong and Jiang, Chang-Hao and Duan, Ying-Jie and Zhao, Yong and Feng, Ye-Fang and Geng, Shi-Mei and Zhang, Zai-Hui and Lu, Jiang and Zhang, Ping and Zhao, Li-Wei and Zhao, Hang and Ma, Yu-Tong and Song, Cheng-Guang and Zhang, Yi and Chen, Hui-Sheng},
title = {Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5–24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study},
journal = {Journal of Stroke},
year = {2023},
volume = {25},
number = {3},
pages = {371--377},
doi = {10.5853/jos.2023.00668}
}
EUVIMED